Although pneumococcal polysaccharide vaccine is a standard preventive intervention — and serves as a "quality indicator" in some settings — controversy over its effectiveness simmers in the ...

Prevenar 13 is a mixture of the outer sugar coating (polysaccharide ... child have ever had an allergic reaction to pneumococcal or diphtheria vaccines, or any of the ingredients listed at ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

The rivalry between Pfizer and MSD in pneumococcal ... on an older polysaccharide technology that does not stimulate the immune response as strongly as the newer conjugate vaccines.

Vaccination with 23-valent pneumococcal polysaccharide vaccines has been shown to elicit only low response rates as a result of immunologic immaturity of the recipients. A study by Meisel et al.

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

Pneumococcal vaccine polyvalent ... patients received either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92% ...

Pneumococcal 20-valent conjugate ... receiving 13-valent pneumococcal conjugate vaccine (Prevnar 13) followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses ...

By contrast, responses to the polysaccharide pneumococcal vaccine, which are T-cell independent, were markedly reduced in patient receiving rituximab compared with methotrexate—just 57% of the ...